Dishman Carbogen Amcis Limited — Investor Meet, 21-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dishman Carbogen Amcis Limited's Q1 FY27 earnings call highlighted a soft quarter with revenue de-growth of 4% to INR 677.6 Cr (from INR 708 Cr) and EBITDA falling to INR 60 Cr (from INR 140.6 Cr), primarily due to a postponed INR 1 Cr order and forex impact.

**Key Takeaways:**

* **Financials:** Q1 saw a loss before tax of INR 51.2 Cr. CDMO EBITDA margin was 6.3%, while Marketable Molecules revenue grew, with margins at 18.6%.

* **Outlook:** Management projects FY27 single-digit revenue growth and similar EBITDA margins. FY28-29 targets double-digit revenue growth and EBITDA closer to 25-26%. Indian operations anticipate 30-35% revenue growth and ~10% operating margin for FY27.

* **Operations:** Successful MFDS inspection at Naroda. Key tech transfers from Switzerland to India are underway to leverage cost efficiencies and boost margins. A new Chief Commercial Officer has been appointed to strengthen sales efforts, and one Phase III molecule recently commercialized.

* **Debt & Refinancing:** Plans are in motion for the promoter entity to raise up to CHF 200 million at 4% interest over 10 years to refinance high-cost Indian debt, expected within 60-90 days.

* **Investor Angle:** Despite Q1 challenges, management remains optimistic, focusing on strategic transfers, commercial expansion, and debt optimization for future growth.